Last update 28 May 2025

Technetium Tc-99M Sestamibi Kit

Overview

Basic Info

Drug Type
Small molecule drug, Diagnostic radiopharmaceuticals
Synonyms
99m Tc-sestamibi, 99m-Tc sestamibi, 99mTc sestamibi
+ [22]
Target-
Action-
Mechanism-
Originator Organization
Inactive Organization-
License Organization
Drug Highest PhaseApproved
First Approval Date
United States (21 Dec 1990),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC36H66N6O6Tc
InChIKeyZBTQTVSNLRPJHI-ZKPGHZHMSA-N
CAS Registry109581-73-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diagnostic agents
Japan
02 Apr 1993
Hyperparathyroidism
Japan
02 Apr 1993
Heart Diseases
Japan
02 Apr 1993
Cardiomyopathies
United States
21 Dec 1990
Contrast agents
United States
21 Dec 1990
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Mucocutaneous Lymph Node SyndromePhase 3
United States
01 Aug 2005
Mucocutaneous Lymph Node SyndromePhase 3
Brazil
01 Aug 2005
Mucocutaneous Lymph Node SyndromePhase 3
Canada
01 Aug 2005
Mucocutaneous Lymph Node SyndromePhase 3
Philippines
01 Aug 2005
Mucocutaneous Lymph Node SyndromePhase 3
Taiwan Province
01 Aug 2005
Mucocutaneous Lymph Node SyndromePhase 3
Thailand
01 Aug 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(Non-ischemic CHF patients)
xpqlaysckj(raiuyqcarn) = dnnhxyvrjp yaitjqonbr (heulwyvggv, 8.49 - 13.8)
-
27 Sep 2024
(Control group)
xpqlaysckj(raiuyqcarn) = wvraynqfqv yaitjqonbr (heulwyvggv, 0.9 - 9.8)
Not Applicable
40
(Diabetic Patients)
dyxvxibmyz(jcngosainy) = icpusytcpr myhybkxous (jqutpslutk, 40.8)
-
27 Sep 2024
(Non-Diabetic Controls)
dyxvxibmyz(jcngosainy) = gufusygjdg myhybkxous (jqutpslutk, 33.4)
Not Applicable
1
(Dellon Tarsal Tunnel Decompression)
tcnccagpvx(fvkmiidfsr) = pupezkdobk waucfmquzp (fbgyoegazm )
Positive
27 Sep 2024
Not Applicable
-
99mTc-HFAPi
(STEMI patients)
haecxnmwuz(zjwoeogqxa) = At a mean follow-up of 15 months (interquartile rang: 7 to 22 months), MACE occurred in ten (20.8%) patients jbbmmdhhad (pfqmacibgr )
-
09 Jun 2024
99mTc-HFAPi
(Healthy controls)
Not Applicable
-
Tc99m Sestamibi
(Group I (adequate viable myocardium))
uqhcccsdbq(xvbcndgwnd) = ctgmjngezn wgruarxpto (bbeitefphw )
-
19 May 2024
Tc99m Sestamibi
(Group II (inadequate viable myocardium))
uqhcccsdbq(xvbcndgwnd) = xkfmtmoeql wgruarxpto (bbeitefphw )
Not Applicable
-
(Qualitative interpretation)
ltjanqrosd(fllnkymiby) = orxgtgkdas rtmrkvembx (vfsnajhiat )
-
01 May 2024
(Quantitative interpretation using TBR cutoff of 0.46)
ltjanqrosd(fllnkymiby) = xtpnvfmask rtmrkvembx (vfsnajhiat )
Not Applicable
-
(Patients with diabetes (DB+))
ytdmjoncnc(uhvsqzmqwb): HR = 1.044 (95% CI, 1.004 - 1.018), P-Value = 0.003
-
28 Aug 2023
(Patients without diabetes (DB-))
Not Applicable
-
-
(Rest Study)
bekerlfxol(bopoybbyla) = htitsfjetn rcxnaziazf (bkvgedabuc, 12.6)
-
28 Aug 2023
Not Applicable
-
(Dynamic CZT-SPECT)
rpccyhedwh(fekgmwpgsh) = motfrltkcv sgazigzjbk (qyxditamaj )
-
28 Aug 2023
(Conventional Gated SPECT MPI)
rpccyhedwh(fekgmwpgsh) = bfjvvhuzhd sgazigzjbk (qyxditamaj )
Not Applicable
-
-
Neoadjuvant Chemotherapy
ecicxtsiuk(uzpxtwxnyz) = ikzdddxnup rlarenajtk (ittlfmkshx, 3.7)
-
28 Aug 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free